Why the study?
Patients with polyvascular disease face very high cardiovascular risk and require intensive lipid-lowering therapy, prompting an assessment of inclisiran's efficacy and safety in this population.
Does inclisiran reduce LDL-C in patients with and without polyvascular disease?
Does inclisiran reduce LDL-C in patients with and without polyvascular disease?
Inclisiran provides effective and sustained LDL-C lowering over 540 days in patients with and without polyvascular disease, with a safety profile similar to placebo except for mild-to-moderate injection site reactions.
No takes yet. Share an insight, caveat, or question.
Supports equivalent intensive LDL-C lowering with inclisiran in PVD; extends phase 3 evidence to this very-high-risk subgroup.
Köenig et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: